Physician
Vidhata Genomics LLC
Vidhata Genomics LLC was paid $616K by Medicaid between Dec 2021 and Apr 2023, across 4 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 74% of everything it billed.
33Billing provider infoVIDHATA GENOMICS LLC
MONMOUTH JUNCTION, NJ 08852
MONMOUTH JUNCTION, NJ 08852
33aNPI1114696101assigned 09/13/2021
33bProvider typeClinical Molecular Genetics Physician
28Total paid$616K
24GClaims21,045
24DCodes billed4
24AFirst – last monthDec 2021 – Apr 2023
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 243 | $968.58 | |
| 2022 | 18,606 | $569K | |
| 2023 | 2,196 | $46K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 74% | 9,347 | 5,135 | $454K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 23% | 8,793 | 4,940 | $144K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 2.9% | 2,860 | 541 | $18K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 45 | 12 | $382.37 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDESAI, SUVAS (LAB DIRECTOR)